People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TP Therapeutics, Inc. | — | Pharmaceuticals | Series C | $126.4M | $2.8B | 2018 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2015 |
| Response Biomedical Corp | — | Biotechnology | Series A | $20.1M | $112.8M | 2011 |
| Sorrento Therapeutics, Inc. | — | Biotechnology | Series A | $19.8M | $66.9M | 2009 |
Lewis J. Shuster at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lewis J. Shuster on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| BIHUA CHEN | 1 | 14 |
| Srinivas Akkaraju | 1 | 10 |
| Simeon George | 1 | 8 |
| Alan Colowick | 1 | 7 |
| George Lee | 1 | 6 |
| MICHAEL DYBBS | 1 | 5 |
| Henry Ji | 1 | 5 |
| Peter A. Thompson | 1 | 5 |
| Daniel Becker | 1 | 5 |
| Antonius Schuh | 1 | 5 |
| Yishan Li | 1 | 4 |
| Nassim Usman | 1 | 4 |
| Joseph D. Keegan | 1 | 4 |
| Kenneth Fong | 1 | 3 |
| Richard G Vincent | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| Curtis Lockshin | 1 | 3 |
| M. Scott Salka | 1 | 2 |
| Ernst-Guenter Afting | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.